scholarly journals LY303366 Exhibits Rapid and Potent Fungicidal Activity in Flow Cytometric Assays of Yeast Viability

1999 ◽  
Vol 43 (4) ◽  
pp. 830-835 ◽  
Author(s):  
Lisa J. Green ◽  
Philip Marder ◽  
Larry L. Mann ◽  
Li-Chun Chio ◽  
William L. Current

ABSTRACT LY303366 is a semisynthetic analog of the antifungal lipopeptide echinocandin B that inhibits (1,3)-β-d-glucan synthase and exhibits efficacy in animal models of human fungal infections. In this study, we utilized flow cytometric analysis of propidium iodide uptake, single-cell sorting, and standard microbiological plating methods to study the antifungal effect of LY303366 on Saccharomyces cerevisiae and Candida albicans. Our data indicate that an initial 5-min pulse treatment with LY303366 caused yeasts to take up propidium iodide and lose their ability to grow. Amphotericin B and cilofungin required longer exposure periods (30 and 180 min, respectively) and higher concentrations to elicit these fungicidal effects. These two measurements of fungicidal activity by LY303366 were highly correlated (r > 0.99) in concentration response and time course experiments. As further validation, LY303366-treated yeasts that stained with propidium iodide were unable to grow in single-cell-sorted cultures. Our data indicate that LY303366 is potent and rapidly fungicidal for actively growing yeasts. The potency and rapid action of this new fungicidal compound suggest that LY303366 may be useful for antifungal therapy.

2019 ◽  
Vol 15 (11) ◽  
Author(s):  
Thays Saynara Alves Menezes-Sá ◽  
Maria de Fátima Arrigoni-Blank ◽  
Andréa Santos da Costa ◽  
Janay De Almeida Santos-Serejo ◽  
Arie Fitzgerald Blank ◽  
...  

Chromosome doubling induction in orchids may benefit their production for resulting in flowers of higher commercial value, larger size and higher content of substances that intensify the color and fragrance when compared with diploid orchids. This work aimed to induce and confirm artificial polyploidization, using flow cytometry and stomatal analysis. Explants were treated with colchicine at concentrations of 0, 2.5, 7.5, and 12.5 mM, for 24 and 48 hours and with oryzalin, at concentrations of 0, 10, 30, and 50 μM, for three and six days. For the flow cytometric analysis, a sample of leaf tissue was removed from each plant, crushed to release the nuclei and stained with propidium iodide. In addition to flow cytometry, the ploidy of the antimitotic treated plants was evaluated by stomata analysis. Young leaves were used where the density, functionality and stomatal index were evaluated. Colchicine provided induction of satisfactory polyploidy in C. tigrina at all concentrations and times of exposure, obtaining a greater number of polyploid individuals in the concentration of 12.5 mM for 48 hours. Oryzalin did not induce chromosome duplication at the tested concentrations.


Cytometry ◽  
2001 ◽  
Vol 43 (2) ◽  
pp. 134-142 ◽  
Author(s):  
Mine Eray ◽  
Mikko M�tt� ◽  
Matti Kaartinen ◽  
Leif C. Andersson ◽  
Jukka Pelkonen

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 28-28 ◽  
Author(s):  
Safa F Mohamad ◽  
Linlin Xu ◽  
Himes R Evan ◽  
Hao Wu ◽  
Marta Alvarez ◽  
...  

Abstract Maintenance of stem cell function is an orchestrated event requiring the participation of multiple cell types within the hematopoietic niche. Precise networking between hematopoietic stem cells (HSC) and these cell types is critical for the maintenance of the stem cell pool. Evidence is accumulating that multiple cell types cooperate to collectively maintain HSC function in the hematopoietic niche. We report here a detailed characterization of calvariae-resident osteomacs (OM) and outline how these cells require cooperation from megakaryocytes (MK) to sustain HSC function. We also describe in detail discriminating phenotypic and functional properties that clearly distinguish OM from marrow-derived macrophages (Mφ). Osteomacs, identified as CD45+F4/80+ cells, were easily detectable in calvarial cell (CC) preparations (3-5% of total CC) collected by the enzymatic digestion of calvariae from 2d-old pups. To assess the effect of MK, a known regulator of osteoblast (OB) proliferation and differentiation, on OM, we performed co-cultures using CC and MK prepared from fetal liver. In the absence of MK, OM did not increase in numbers over a period of 5 days in culture and remained approximately 5% of total cultured cells. However, in the presence of MK, OM significantly increased to become between 25% and 30% of total cells demonstrating that MK regulate OM proliferation. Clonogenic assays established that OM support hematopoiesis enhancing activity of OB and that this activity can be upregulated by MK. Interestingly, marrow-derived Mφ were unable to mediate the same hematopoiesis enhancing activity regardless of whether MK were present in the co-culture or not. These results were validated via primary and secondary transplantations in lethally irradiated hosts whereby the highest repopulating potential was observed among marrow-derived LSK cells co-cultured for 5 days with a mixture of OB, OM, and MK. Using eight surface markers and flow cytometric analysis, we established that although marrow-derived Mφ and OM share many phenotypic similarities (CD45, F4/80, CD68, CD11b, Mac2, and GR-1), only OM expressed MCSFR and CD166, thus providing a distinct and unique profile for these cells. To assess changes in pathway activation between resting and MK-activated OM, we performed single cell genomic analysis. This approach detected the upregulation of several canonical pathways important in HSC maintenance such as Ephrin receptor signaling, PDGF signaling, and leukocyte extravasation signaling in MK-stimulated OM. Single cell genomic analysis between CC-derived OM and marrow-derived Mφ (isolated from each tissue as CD45+F4/80+ cells) revealed 39 genes to be significantly different between the two cell types. Strikingly, many genes such as IGF1, KITL and NOTCH2 that have previously been implicated in HSC regulation were upregulated in OM. MCSFR1 a known regulator of proliferation, differentiation and survival of Mφ was also upregulated in OM corroborating the data previously collected from flow cytometric analyses. However, OM did not respond to exogenous MCSF stimulation suggesting that MCSF alone is not sufficient to induce OM proliferation or that direct contact with MK is required for induction of proliferation. To investigate changes at the protein translational level, we examined both cell types using CyTOF and a panel of 24 surface and intracellular antibodies. The surface marker CD169 which was previously associated with HSC retention when present on cellular components of the hematopoietic niche was expressed on OM but not on Mφ. Intriguingly, OM expressed both CD86 and CD206 which are known M1 and M2 Mφ markers, respectively. TNF-α, TIMP2, FGF2 and MCP1 which are known HSC regulators were also upregulated in OM. Finally, the majority of OM expressed embigin and IL-18, both of which have been implicated in the maintenance of HSC function. These data demonstrate that although bone-associated OM share many properties with marrow-derived Mφ, they are phenotypically and functionally distinct and are critical for the maintenance of HSC function. Furthermore, the function of OM, and consequently that of the two components of CC, namely OB and OM, is significantly augmented by interactions with MK demonstrating that the crosstalk between OM, OB and MK form a novel network in supporting HSC function. Disclosures No relevant conflicts of interest to declare.


2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Harumichi Itoh ◽  
Shimpei Nishikawa ◽  
Tomoya Haraguchi ◽  
Yu Arikawa ◽  
Masato Hiyama ◽  
...  

This study aimed to demonstrate single-cell phosphospecific flow cytometric analysis of canine and murine adipose-derived stem/stromal cells (ADSCs). ADSCs were obtained from clinically healthy laboratory beagles and C57BL/6 mice. Cell differentiation into adipocytes, osteocytes, and chondrocytes was observed for the cultured canine ADSCs (cADSCs) and murine ADSCs (mADSCs) to determine their multipotency. We also performed single-cell phosphospecific flow cytometric analysis related to cell differentiation and stemness. Cultured cADSCs and mADSCs exhibited the potential to differentiate into adipocytes, osteocytes, and chondrocytes. In addition, single-cell phosphospecific flow cytometric analysis revealed similar β-catenin and Akt phosphorylation between mADSCs and cADSCs. On the other hand, it showed the phosphorylation of different Stat proteins. It was determined that cADSCs and mADSCs show the potential to differentiate into adipocytes, osteocytes, and chondrocytes. Furthermore, a difference in protein phosphorylation between undifferentiated cADSCs and mADSCs was identified.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 1317-1317
Author(s):  
Alisa B. Lee-Sherick ◽  
Kelly Menachof ◽  
Kristen M. Eisenman ◽  
Amy McGranahan ◽  
Colleen McGary ◽  
...  

Abstract Abstract 1317 Acute myelogenous leukemia (AML) is difficult to treat successfully in both adult and pediatric patients using conventional chemotherapy. Mutated or aberrantly expressed proteins on the cell surface of myeloblasts provide a focus for targeted therapy which could potentially augment therapeutic outcome, decrease toxicity to normal tissues, and/or provide a therapy option for those who are not able to tolerate conventional therapy. We report here that the Mer receptor tyrosine kinase is upregulated in approximately 80% of AML cell lines and patient samples, and explore the therapeutic potential of Mer inhibition. We assessed the prevalence of Mer expression in AML. Western blot and flow cytometric analysis demonstrated expression of Mer in greater than 85% (12/14) of AML cell lines. Mer expression was also assessed at the time of diagnosis and relapse in both pediatric and adult patient samples using flow cytometry. We found that Mer was expressed on leukemic blasts in 80% of 36 pediatric and 100% of 10 adult patients at the time of diagnosis with AML. Additionally, 100% of 11 patients expressed Mer at the time of relapse. Furthermore, when analyzing patient samples at relapse compared to the same patient's diagnostic sample, there was a trend toward increased Mer expression. This is in contrast to normal bone marrow myeloid progenitors from healthy donors, which express little or no Mer. Using two independent shRNA constructs directed against Mer, we analyzed the effects of Mer inhibition in two Mer expressing AML cell lines. Mer knock-down and control cell lines were assessed for apoptosis by flow cytometry after serum starvation and staining with Yo-Pro-1 iodide and propidium iodide. Compared to AML cell lines transduced with a non-silencing control shRNA (shControl), cell lines expressing reduced levels of Mer protein demonstrated significantly more apoptosis (p<0.05). Additionally, when these cell lines were plated in equal number in methylcellulose, cell lines with reduced Mer expression demonstrated decreased colony forming potential compared to shControl cells (p<0.01). Mer knock-down and control cell lines were injected into NOD-SCID-gamma mice after sublethal irradiation and the mice were monitored for development of leukemia. Mice injected with myeloblasts expressing decreased levels of Mer demonstrated significantly prolonged symptom-free survival compared to mice transplanted with shControl AML cells (p<0.001). To further explore the effects of Mer inhibition in AML, we used a novel small molecule tyrosine kinase inhibitor (UNC1666), which has high specificity to Mer. Three Mer expressing AML cell lines were treated with UNC1666 in vitro; treatment reduced phosphorylation of Mer and the downstream signaling molecules ERK1/2 and STAT6. Additionally, treatment with UNC1666 resulted in significant induction of apoptosis (p<0.05) by flow cytometric analysis after staining with Yo-Pro-1 iodide and propidium iodide, and dose-dependent inhibition of colony formation in soft agar, when compared to vehicle treated cells In summary, the upregulation of Mer expression in patient samples and the functional effects on survival with Mer shRNA knockdown help validate Mer as a new and attractive AML therapeutic target. Furthermore, a novel Mer tyrosine kinase inhibitor decreased myeloblast cell survival, providing evidence that Mer is a druggable target in AML. Disclosures: Kireev: WO: Pyrazolopyrimidine Compounds for the Treatment of Cancer. WO Patent 2011146313, 2011, Pyrazolopyrimidine Compounds for the Treatment of Cancer. WO Patent 2011146313, 2011 Patents & Royalties. Liu:WO: Pyrazolopyrimidine Compounds for the Treatment of Cancer. WO Patent 2011146313, 2011, Pyrazolopyrimidine Compounds for the Treatment of Cancer. WO Patent 2011146313, 2011 Patents & Royalties. Wang:WO: Pyrazolopyrimidine Compounds for the Treatment of Cancer. WO Patent 2011146313, 2011, Pyrazolopyrimidine Compounds for the Treatment of Cancer. WO Patent 2011146313, 2011 Patents & Royalties. Frye:WO: Pyrazolopyrimidine Compounds for the Treatment of Cancer. WO Patent 2011146313, 2011, Pyrazolopyrimidine Compounds for the Treatment of Cancer. WO Patent 2011146313, 2011 Patents & Royalties. Graham:University of Colorado: This author has provisional patent considerations for iMer, This author has provisional patent considerations for iMer Patents & Royalties.


1986 ◽  
Vol 64 (3) ◽  
pp. 453-459 ◽  
Author(s):  
Takao Hoshino ◽  
Tadashi Nagashima ◽  
Judith A. Murovic ◽  
Charles B. Wilson ◽  
Michael S. B. Edwards ◽  
...  

✓ Thirty-eight patients undergoing surgical removal of neuroectodermal tumors of the central nervous system were given a 1-hour intravenous infusion of bromodeoxyuridine (BUdR), 150 to 200 mg/sq m, to label tumor cells in the deoxyribonucleic acid (DNA) synthesis phase (S-phase). The excised tumor specimens were divided into two portions: one was fixed with 70% ethanol and embedded in paraffin and the other was digested with an enzyme cocktail to make a single-cell suspension. The paraffin-embedded tissues were stained by an indirect peroxidase method using anti-BUdR monoclonal antibody (MA) as the first antibody. Single-cell suspensions were reacted with fluorescein isothiocyanate (FITC)-conjugated anti-BUdR MA's for flow cytometric analysis. S-phase cells that had incorporated BUdR into their DNA were well stained by both methods. The percentage of BUdR-labeled cells, or S-phase fraction, was calculated in tissue sections by microscopic examination and in single-cell suspensions by flow cytometric analysis. The biological malignancy of the tumors was reflected in the S-phase fractions, which were 5% to 20% for glioblastoma multiforme, medulloblastoma, and highly anaplastic astrocytoma, but less than 1% in most moderately anaplastic astrocytomas, ependymomas, and mixed gliomas. Two juvenile pilocytic astrocytomas and two low-grade astrocytomas from children had high S-phase fractions despite the fairly benign and slow-growing nature of these tumors. These results indicate that the S-phase fraction obtained immunocytochemically with anti-BUdR MA's may provide useful information in estimating the biological malignancy of human central nervous system tumors in situ.


Sign in / Sign up

Export Citation Format

Share Document